DyNAbind GmbH, Tatzberg 47, 01307 Dresden

Press Release
For immediate distribution

Michael Thompson, Ph.D.
Chief Executive Officer

DyNAbind and Salipro Biotech enter collaboration agreement

Dresden, Germany / Stockholm, Sweden, 09 November 2020 – DyNAbind GmbH and Salipro Biotech AB are teaming up to tackle drug discovery against challenging membrane protein targets! By bringing together DyNAbind's proprietary DNA-Encoded Library (DEL) technologies with Salipro's proprietary membrane stabilizing platform technology, the teams aim to accelerate the development of novel drugs for these contemporary targets.

Michael Thompson, co-founder and CEO of DyNAbind, explains the importance of this collaboration: "Membrane proteins represent an increasingly important, yet difficult-to-drug class of protein targets. Together with Salipro Biotech, we aim to set up a comprehensive discovery process to address this specific protein target group, and continuing to expand our target space to enable our current and future pharma partners to develop completely novel first-in-class medicines."

Jens Frauenfeld, co-founder and CEO of Salipro Biotech AB: "We are excited to develop novel hits for challenging drug targets such as GPCR and Ion Channels with DyNAbind. Generating drugs against membrane proteins remains a most challenging task, but by combining the strengths of our Salipro® platform technology for membrane proteins with the Dynamic Library technology of DyNAbind, we will open up entirely new possibilities for us and our partners to make the undruggable druggable."

Financial terms of the collaboration agreement were not disclosed.

About DyNAbind

DyNAbind GmbH is a privately held company based in Dresden, Germany, offering a next-generation platform of DNA-Encoded Library (DEL) technologies for drug discovery and optimization. DyNAbind's founders have years of experience in developing and working with DEL technologies, which has driven the development of the novel Dynamic Library platform. By specifically tuning a DNA architecture for transient interactions, fragment molecules in the library dynamically self-assemble and rearrange themselves into ideal binding structures, offering dramatically improved signal-to-noise ratios and reduced false positive hit rates. Follow-up quantitative hit validation can begin without the need for hit resynthesis, allowing meaningful results to arrive in days instead of months.

Our entire team at DyNAbind is dedicated to working with our partners to develop and implement the most effective discovery and optimization programs for any drug target. Whether your program is coming from the pharma, biotech or academic sector, we're motivated to help you find the best path to higher-quality, more relevant medicinal chemistry starting points.

About Salipro Biotech AB:

Salipro Biotech is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins.

The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design.

To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.

Press contacts:

DyNAbind GmbH
Nadine Schmieder-Galfe
Director Marketing
+49 (0)351 7999 2923
info@dynabind.com
http://www.dynabind.com

Salipro Biotech AB
Maria Lisa Knudsen
Business Developer
+46 (0)72 939 5018
maria.knudsen@salipro.com
https://www.salipro.com